Citations

Clear

1056 citation(s) found for "Sharma, P".

Endoscopic Ultrasound-Guided Gallbladder Drainage
Baron, Todd H., Umar, Shifa, Lam, Gregory, Pannala, Rahul , Amateau, Stuart, Tielleman, Thomas, Khodorskiy, Dmitriy O., Companioni, Rafael Ching, Bedi, Gurneet, Torres, Ricardo Marrero, Chudy‐Onwugaje, Kenechukwu, Bhogal, Neil, Gelrud, Andrés , Gabr, Moamen, Shin, Eun Ji, Adler, Douglas G., Irani, Shayan , Kushnir, Vladimir, Sachdev, Mankanwal S., Sharma, Neil, Tyberg, Amy , Widmer, Jessica, Widmer, Jessica L , Canakis, Andrew , Baron, Todd H. , Amateau, Stuart K. , Tielleman, Thomas , Companioni, Rafael A. Ching, Chudy‐Onwugaje, Kenechukwu , Gabr, Moamen , Shin, Eun Ji , Adler, Douglas G. , Kushnir, Vladimir , Sachdev, Mankanwal S. , Sharma, Neil

Mayo Clinic

Journal of Clinical Gastroenterology | July 23, 2026 | Volume: 60 | Issue: 8 | Pages: 685-694

10.1097/mcg.0000000000002409 | PMID 42490390 Get It

Acute cholecystitis affects ∼200,000 individuals annually in the United States, with laparoscopic cholecystectomy as the gold standard treatment. However, in high-risk surgical candidates, alternative drainage methods are necessary. Percutaneous transhepatic gallbladder drainage (PT-GBD) has traditionally served as the primary alternative intervention, offering rapid decompression, but is limited by a negative impact on the patient’s quality of life, the risk of long-term or even permanent tube placement, adverse events, and high recurrence rates. Endoscopic approaches, such as endoscopic transpapillary gallbladder drainage (ET-GBD) and, more recently, endoscopic ultrasound-guided gallbladder drainage (EUS-GBD), have emerged as viable alternatives to PT-GBD. EUS-GBD, first introduced in 2007, offers technical and clinical outcomes comparable to PT-GBD with fewer adverse events, shorter hospital stays, and lower rates of recurrence. The introduction of lumen-apposing metal stents (LAMS) has revolutionized EUS-GBD, simplifying deployment and enabling subsequent internal gallbladder access, which allows additional interventions such as cholecystoscopy and stone removal. EUS-GBD is now supported by international guidelines, and 1 device has achieved FDA approval for the management of acute cholecystitis in nonsurgical candidates. Proper patient selection is essential, guided by multidisciplinary evaluation, with EUS-GBD contraindicated in specific scenarios such as gallbladder perforation, coagulopathy, and large-volume ascites. Technical considerations include choice of access site (transgastric versus transduodenal), stent type, and procedural route [direct (freehand) or wire-guided]. Postprocedural care and stent management remain variable and nonstandardized. Emerging data suggest that interval cholecystectomy can still be performed safely after EUS-GBD. As adoption of EUS-GBD with LAMS expands, structured training and standardization of practice are crucial to optimizing outcomes.
Quantitative Prognostic Modeling in Aneurysmal Subarachnoid Hemorrhage: Multicenter Validation of the eSAH Score
Salman, Saif, Moy, Constantin Graf von , Haidenberger, Flora, Ahmed, Mahlika, Foettinger, Fabian, Sharma, Rohan, Gutierrez-Aguirre, Salvador, Toledo, Otávio de, Patel, Vishal , Yujia-Wei, David, Brandmeir, Nicholas, Lakkaraju, Kausik , Ombada, Mutaz , Aguilar-Salinas, Pedro, Miller, David, Erickson, B E, Hanel, Ricardo, Tawk, Rabih, Byrne, Richard, Salman, Saif , Haidenberger, Flora, Gutierrez‐Aguirre, Salvador F. , Toledo, Otavio F. De , Patel, Vishal, Jahromi, Behnam Rezai , Brandmeir, Nicholas J. , Erickson, B E, Tawk, Rabih G. , Freeman, William D.

Mayo Clinic

No container title available | July 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.18.26358390 Get It

Abstract Background aneurysmal subarachnoid hemorrhage (aSAH) is neurological emergency associated with substantial mortality and disability. Current grading systems such as the modified Fisher Scale (mFS) and World Federation of Neurological Societies (WFNS) score, rely on semiquantitative and examination based assessments. Hence, they demonstrate limited predictive precision. The enhanced subarachnoid hemorrhage (eSAH) score is a simplified quantitative model integrating age, Glasgow Coma Scale (GCS), and cisternal subarachnoid hemorrhage volume (SAHV) to predict clinical outcomes after aSAH. Methods We performed a retrospective multicenter cohort study that included 1088 patients across three tertiary-care centers the United States. Predictive performance for unfavorable functional outcome, in-hospital mortality and delayed cerebral ischemia (DCI) was evaluated using receiver operating characteristic (ROC) analysis and area under the curve (AUC). Comparative analyses were performed and compared to the WFNS and mFS grading systems. Results the eSAH score demonstrated excellent discrimination for unfavorable functional outcome at discharge ( AUC 0.89 ) and in-hospital mortality (AUC 0.87). The DCI subscore demonstrated good discriminatory performance for predicting DCI (AUC 0.77). Compared with conventional grading systems, this was superior to both the WFNS (AUC 0.75) and the mFS ( AUC 0.70). increasing eSAH scores were additionally associated with progressively higher rates of mortality and unfavorable functional outcomes. Conclusion the eSAH score demonstrates strong external validity, reproducibility and superior predictive performance compared with conventional grading systems in a large multicenter cohort. These findings support the clinical utility of quantitative hemorrhage burden integration for early risk stratification in patients with aSAH.
Glomerulus-Targeted Nanotherapy via Collagen IV-α3 Binding Enhances Renal Immunoregulation in Lupus Nephritis
Wang, L Q, Markoutsa, Eleni, Venkatadri, Rajkumar , Sharma, Rahul, Esquivel, Carlos, Patne, Akshata, Wei, Jin, Zhang, J, Williams, Kristof , Lawless, William, Muskan, Amtul, Fu, Liying, Mayilsamy, Karthick, Ss, Mohapatra, Mohapatra, Shyam, Wang, Lei , Esquivel, Carlos O. , Zhang, Jie, Fu, Liying, Mayilsamy, Karthick , Mohapatra, Subhra, Mohapatra, Shyam, Liu, Ruisheng

Mayo Clinic

No container title available | July 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.14.738533 | PMID 42538937 Get It

ABSTRACT Lupus nephritis requires long-term immunosuppressive therapy, which is often associated with severe systemic side effects. Therefore, new therapeutic strategies that maintain high efficacy while minimizing adverse effects is essential. Although nanomedicine has advanced systemic and kidney-targeted drug delivery, a reliable method for glomerulus-specific delivery is lacking. Collagen IV (Col4)-alpha 3, located in the glomerular basement membrane (GBM) at the blood–tissue interface through fenestrated capillary endothelium, represents an ideal target for glomeruli delivery. Herein, we developed a novel liposomal nanoparticle conjugated with a Col4-alpha 3 binding peptide (Col4-α3-NPs) for selective glomerular targeting. Prednisolone-loaded Col4-α3-NPs were administered to lupus-prone mice twice weekly for 8 weeks. Kidney injury and function were evaluated biweekly, and renal immune cell populations were analyzed by flow cytometry at study completion. The results show that rhodamine-labeled NPs predominantly accumulate in kidney glomeruli 48 hours after intravenous injection. The Col4-NP system demonstrated stable and prolonged release of the encapsulated drug for over 48 hours. Lupus-prone mice treated with prednisolone-loaded Col4-NPs showed significantly improved renal function and histology, including a 30% increase in glomerular filtration rate (GFR), a 56% reduction in proteinuria, and decreased IgG deposition and fibrosis. Notably, treatment also enhanced renal regulatory T cell (Treg) populations. These findings suggest that glomerulus-targeted Col4-α3-NPs hold significant translational promise. This platform may offer an effective, site-specific treatment for lupus nephritis while minimizing systemic side effects and could be adapted for other glomerular diseases requiring targeted therapy.
Comparative Seizure Outcomes of Vagus Nerve Stimulation, Deep Brain Stimulation, and Their Combination in Lennox–Gastaut Syndrome
Kuo, Cheng‐Yen , Singh, Raunak, Sharma, Shelja, Nguyen, Ryan D. , Wong‐Kisiel, Lily C. , Starnes, Keith , Gregg, Nicholas M. , Gompel, Jamie Van, Miller, Kai J., Worrell, Gregory A. , Wong-Kisiel, Lily C. , Van Gompel, Jamie, Lundstrom, Brian Nils , Worrell, Gregory A , Gregg, Nicholas M , Singh, Raunak , Starnes, Donnie Keith , Kuo, Cheng‐Yen , Nguyen, Ryan Toan Dinh , Gompel, Jamie J. Van , Miller, Kai J. , Lundstrom, Brian N.

Mayo Clinic

Annals of Neurology | July 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ana.78308 | PMID 42446202 Get It

Objective Lennox–Gastaut syndrome (LGS) is a severe treatment‐resistant epilepsy. Although vagus nerve stimulation (VNS) and deep brain stimulation (DBS) are established therapies, comparative data and the impact of dual neuromodulation remain limited. We compared seizure outcomes across VNS, DBS, and combined DBS + VNS therapy in LGS. Methods This retrospective cohort study at Mayo Clinic (2005–2024) included LGS patients treated with VNS and/or DBS . Seizure frequency was assessed at 6, 12, and 24 months post‐stimulation. Responder was defined as 50% or more seizure reduction. Results Forty patients were included (42% female, median, 150 seizures/month). Eleven patients underwent sequential VNS followed by DBS and contributed data to 2 treatment epochs, yielding 3 treatment groups: VNS alone (n = 29), DBS alone (n = 12), and DBS + VNS (n = 10). At 24 months, median seizure reduction rate was comparable between VNS (50%; 95% confidence interval [ CI], 44–75%) and the overall DBS cohort (59%, 95% CI, 33–86%) ( p = 0.54). However, a significant difference emerged when comparing the 3 treatment arms ( p = 0.027). Specifically, DBS + VNS therapy yielded significantly greater median reduction rate (81%, 95% CI, 60–99%) than DBS alone (43%, 95% CI, 0–58%) ( p adj = 0.027) or VNS alone (50%, 95% CI, 44.4–75.0%) ( p adj = 0.048). Four patients attained sustained seizure freedom above 1 year at last follow‐up. Interpretation VNS and DBS provide comparable seizure reduction in LGS over a 2‐year follow‐up period. DBS + VNS was associated with further improvements in seizure reduction in this small, retrospective dataset. This possibility warrants further investigation. ANN NEUROL 2026
Community-informed development of an in-person forum to promote breast cancer screening and research preparedness in rural and low-socioeconomic status women
Sharma, Pravesh , Imsande, Kaylynn G., Vitriago, Anni, Seibel, Maria, Pritchett, Josh, Rudder, B. de, Tran, Linh T., Larson, Stephanie L., Flock, Carolyn, Murphy, Crystal, Asiedu, Gladys B. , Odedina, Folakemi T., Lynch, Brian, Haddad, Tufia C. , Pritchett, Joshua , Rudder, Bongi, Larson, Stephanie, Patten, Christi , Asiedu, Gladys B , Haddad, Tufia, Sharma, Pravesh , Imsande, Kaylynn G, Larson, Stephanie, Flock, Carolyn R., Murphy, Crystal, Patten, Christi A. , Odedina, Folakemi

Mayo Clinic

Journal of Clinical and Translational Science | July 13, 2026 | Volume: 10 | Issue: 1 | Pages: No page available

10.1017/cts.2026.10788 | PMID 42534402 Get It

Abstract Rural and low-socioeconomic status women face social determinants of health barriers leading to disproportionately low rates of breast cancer screening and markedly reduced participation in clinical trials. To address this gap, we developed the WeCARE (Women’s Engagement for Cancer Awareness, Resources, and Education) intervention using a community-engaged approach. This paper describes how Community Advisory Board feedback informed the development of Mayo Clinic Health System’s WeCARE intervention components. Their input was systematically analyzed using the Consolidated Framework for Implementation Research (CFIR 2.0) to identify determinants of acceptability, appropriateness, and feasibility and to guide actionable refinements to intervention content and delivery.
Insulin autoimmune hypoglycemia unmasking monoclonal gammopathy in type 2 diabetes
Prasad, S. , Sharma, A K , Parmar, Vidhi, Jindal, Tanisha , Kothia, Darpan, Bavaria, Deep, Prasad, Sai , Kothia, Darpan

Mayo Clinic

JCEM Case Reports | July 13, 2026 | Volume: 4 | Issue: 8 | Pages: No page available

10.1210/jcemcr/luag190 | PMID 42438805 Get It

Abstract Insulin autoimmune syndrome (IAS), also known as Hirata disease, is a rare cause of spontaneous hypoglycemia due to circulating insulin autoantibodies, most commonly described in East Asian individuals and those exposed to sulfhydryl-containing drugs. We describe a 58-year-old South Asian man with type 2 diabetes mellitus who presented with recurrent fasting and postprandial hypoglycemia despite cessation of all glucose-lowering medications. A spontaneous episode confirmed Whipple triad: plasma glucose 38 mg/dL (SI: 2.1 mmol/L; reference range, 70-99 mg/dL [SI: 3.9-5.5 mmol/L]), markedly elevated serum insulin at 156 µIU/mL (SI: 1083 pmol/L; reference range, 2.6-24.9 µIU/mL [SI: 18-173 pmol/L]), and C-peptide of 5.8 ng/mL (SI: 1.9 nmol/L; reference range, 0.5-2.0 ng/mL [SI: 0.17-0.66 nmol/L]), with a negative sulfonylurea screen and markedly elevated insulin autoantibody titers. Polyethylene glycol precipitation confirmed antibody-bound insulin sequestration. Workup identified IgG-kappa monoclonal gammopathy of undetermined significance as the probable precipitant. Dietary modification, oral glucocorticoids, and acarbose achieved near-complete resolution of hypoglycemia with declining autoantibody titers over 4 weeks. This case highlights the importance of considering IAS in unexplained hyperinsulinemic hypoglycemia and the need to screen for plasma cell dyscrasias in atypical presentations.
Real-World Practice in Secondary Stroke Prevention Following Embolic Stroke of Undetermined Source
Nour, Hassan Aboul , Siegler, James E. , Thompson, Sean, Glover, Patrick , Daniel, J, Penckofer, Mary , Smith, M A, Yaghi, Shadi , Chen, L, Kerrigan, Deborah , Kirchhoffer, Kaitlyn, Kam, Wayneho , Melkumova, Emiliya , Lineback, Christina , Thottempudi, Neeharika , Heaton, Sharon, Linares, Guillermo , Singh, Eesha , Fernández, Camilo José Albert, Dumitrașcu, Oana , Bowman, Anna, Porto, Camelia Valhuerdi, Chahien, Dalia, Herpich, Franziska , Kang, Jieun , Nelson, Ashley , Shahrivari, Mahan, Khezri, Nicole, Lewis, Skylar, Sathya, Anvitha , Leung, Lester Y. , Eklund, Kelsey , Rojas-Soto, Diana , Nedelcu, Simona , Kasab, Sami Al , Coevering, Russell J. Van, Thon, Jesse , Aboul-Nour, Hassan , Siegler, James E , Thompson, Sean L , Glover, Patrick , Daniel, Jean-Philippe Auguste , Smith, Matthew M , Ro, Jennifer , Chen, Lucia , D'Souza, Marissa , Khasiyev, Farid , Kerrigan, Deborah , Sharma, Richa , Aziz, Yasmin , Kirchhoffer, Kaitlyn , Kam, Wayneho , Melkumova, Emiliya , Sloane, Kelly L , Lineback, Christina M , Thottempudi, Neeharika , Heaton, Sharon , Linares, Guillermo , Almallouhi, Eyad , Stretz, Christoph , Dumitrascu, Oana M , Culbertson, Collin J , Elangovan, Cheran , Bowman, Anna , Valhuerdi Porto, Camelia , Chahien, Dalia , Herpich, Franziska , Farooqui, Mudassir , Kang, Jieun , de Havenon, Adam H , Nelson, Ashley , Shahrivari, Mahan , Stamm, Brian , Khezri, Nicole , Lewis, Skylar , Sathya, Anvitha , Leung, Lester Y , Eklund, Kelsey , Rojas-Soto, Diana , Nedelcu, Simona , Al Kasab, Sami , Thon, Jesse , Jillella, Dinesh V , Nahab, Fadi B , Yaghi, Shadi , Penckofer, Mary , D’Souza, Marissa , Khasiyev, Farid , Sharma, Richa , Aziz, Yasmin , Almallouhi, Eyad , Stretz, Christoph , Elangovan, Cheran , Havenon, Adam de , Stamm, Brian , Coevering, Russell J. Van , Jillella, Dinesh

Mayo Clinic

Neurology Clinical Practice | July 10, 2026 | Volume: 16 | Issue: 4 | Pages: No page available

10.1212/cpj.0000000000200631 | PMID 42430672 Get It

Heterogeneous Treatment Effects in HFpEF: Distinguishing Drug-Specific Response from Prognostic Phenotypes Across Randomized Trials
Santana, Clodomir, Katayama, Asuka, Ballal, Aditya , Liem, David A., Chen, C , Nuno, Miriam, Ebong, Imo, Zhang, Xiao-Dong, Izu, Leighton, Alagna, Laura , Borlaug, Barry A., Butler, Javed, Chirinos, Julio A. , Chutkow, William A., Desai, Akshay S., Desvigne-Nickens, Patrice, Givertz, Michael M., Khan, Sadiya S., Kitzman, Dalane W., Lewis, Gregory D., Redfield, Margaret M., Shah, Sanjiv J., Sharma, Kavita, Taylor, Jennifer , Tinsley, Emily, Wong, Renee, Shah, Sanjiv J., Sirish, Padmini , Liem, David A. , Bidwell, Julie T. , Nuño, Miriam , Ebong, Imo , Izu, Leighton T. , Alagna, Laura, Pesce, Lorenzo L. , Sisk, Ryan K. , Borlaug, Barry A. , Butler, Javed , Desai, Akshay S , Desvigne‐Nickens, Patrice , Givertz, Michael M. , Khan, Sadiya S. , Kitzman, Dalane W. , Lewis, Gregory D. , Rasmussen‐Torvik, Laura J. , Redfield, Margaret M. , Sharma, Kavita , Taylor, Jennifer L., Shah, Sanjiv J , López, Javier E. , Chiamvimonvat, Nipavan , Cadeiras, Martín

Mayo Clinic

No container title available | July 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.06.26357251 | PMID 42465912 Get It

Abstract Background Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome comprising multiple pathophysiological phenotypes. HFpEF trials have largely enrolled diverse populations and reported average treatment effects, consistently yielding neutral results that may obscure drug-specific benefits within distinct subgroups. To address this issue, we employ an interaction-based that incorporates treatment-by-variable interactions to uncover drug-specific responses. Methods We leveraged four HFpEF clinical trials (TOPCAT, RELAX, NEAT-HFpEF, INDIE-HFpEF) and developed a framework comprising two complementary approaches. The first employed a prognostic responder model to evaluate whether conventional responder definitions reflect treatment-specific benefit or instead capture favorable clinical trajectories common to both treatment and placebo groups. The second used an interaction-based individual treatment effect (ITE) modeling to identify baseline variables that modify therapy effect, distinguishing drug-specific response from prognostic phenotypes. Results Although the prognostic responder model demonstrated good discrimination, further analisys suggested it primarily captured a prognostic signal associated with favorable clinical trajectories common to both treatment and placebo arms. In contrast, the ITE model identified distinct, drug-specific effect modifiers across trials (cardiorenal-inflammatory for spironolactone (TOPCAT), NO-mediated anti-inflammatory for isosorbide mononitrate (NEAT-HFpEF), afterload-reducing for inorganic nitrite (INDIE-HFpEF), and anti–volume-overload for sildenafil (RELAX). Each ITE model demonstrated significance only within its own trial suggesting drug-specific signal. Conclusions The proposed method identifies mechanism-specific effect modifiers, and uncovers clinically meaningful heterogeneity in treatment response, which is not captured by conventional MCID-based approaches. Although exploratory, these findings support phenotype-guided therapy in HFpEF and argue for phenotype-informed trial design to enhance treatment-effect detection and therapy targeting. Graphical Abstract
Neurophysiological mechanisms of breathing-based well-being practices: a narrative review for clinical application
Veerareddy, Vaishnavi, 홍이수, Nycklemoe, Marin, Kandimalla, Mahathi, Sharma, Vamika, Kung, Tiffany L., Osman, Rowa, Min, Paul H., Hong, Isu, Sharma, Pravesh , Veerareddy, Vaishnavi, Nycklemoe, Marin, Kung, Tiffany L., Lim, Seokbeen , Kandimalla, Karunya K. , Lapid, Maria I.

Mayo Clinic

Frontiers in Psychiatry | July 8, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fpsyt.2026.1774490 | PMID 42487760 Get It

Breathing is a physiological process that extends beyond gas exchange, linking neural, cardiovascular, glymphatic, and autonomic systems. This narrative review summarizes how breathing-based practices modulate physiological processes in the body and brain, emphasizing their applicability in clinical care. Regulating the pace and depth of breathing, particularly with relaxed exhalation, may engage vagal pathways that lower heart rate and blood pressure and promote a shift toward increased parasympathetic tone relative to sympathetic activity. Neuroimaging studies show that controlled breathing reduces activity in stress-related brain regions while enhancing networks supporting calm attention and emotional steadiness. Changes in breathing depth also influence cerebrospinal fluid movement, though direct evidence of waste clearance in humans is lacking. This review identifies populations requiring caution, including individuals with panic symptoms, significant cardiopulmonary disease, or pregnancy. Clinicians should distinguish between breathing-only and multimodal protocols when interpreting research findings, as combined interventions preclude attribution of benefit to breathing alone. Study design quality, particularly the use of active rather than waitlist controls, should inform how effect sizes are interpreted. Breathing practices are not a replacement for medical treatment but may represent accessible, low-cost adjuncts for stress reduction and cardiovascular regulation.